Can Wogonin be Used in Controlling Diabetic Cardiomyopathy?

Shahzad Khan1, Mohammad A Kamal2,3,4

  • 1Department of Pathophysiology, Wuhan University School of Medicine, Hubei, Wuhan V, China.

Insights

Wogonin, a plant-derived flavonoid, shows promise in treating diabetic cardiomyopathy (DCM). This review explores its potential therapeutic benefits for cardiovascular complications associated with diabetes mellitus (DM).

Area of Science:

  • Pharmacology
  • Cardiology
  • Natural Products

Background:

  • Diabetes Mellitus (DM) causes metabolic derangements, notably leading to diabetic cardiomyopathy (DCM).
  • Cardiovascular complications in DM can cause cardiac failure, independent of ischemic heart disease.
  • Diabetic cardiomyopathy (DCM) represents a significant health concern in diabetic patients.

Purpose of the Study:

  • To review the therapeutic potential of Wogonin for treating diabetic cardiomyopathy (DCM).
  • To explore Wogonin's properties and safety profile in the context of cardiovascular disease.
  • To highlight Wogonin as a potential plant-derived treatment for DCM.

Main Methods:

  • Literature review of studies on Wogonin and its effects.
  • Analysis of Wogonin's pharmacological properties, including anti-inflammatory, antioxidant, and anti-apoptotic effects.
  • Evaluation of safety and toxicity data for Wogonin.

Main Results:

  • Wogonin exhibits antioxidant, anti-inflammatory, anti-viral, and anti-thrombotic properties.
  • Wogonin has demonstrated the ability to alleviate apoptosis and ER stress in cells.
  • Wogonin possesses a favorable safety profile with minimal organ toxicity.

Conclusions:

  • Wogonin shows significant therapeutic potential for managing diabetic cardiomyopathy (DCM).
  • Its multifaceted properties, including anti-apoptotic and anti-ER stress effects, are beneficial for cardiovascular health.
  • Wogonin represents a promising natural compound for further investigation in DCM treatment.

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
492
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
488
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
433
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
521
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
321
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
361